Meta AnalysisID 2205
氟奋乃静癸酸酯（给药时机）用于精神分裂症患者 [Cochrane方案]
CRD42017083392
To investigate the benefits and harm of administering fluphenazine decanoate at different time intervals for people with schizophrenia.
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Ingredient: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 2205
- Evidence Id
- 10763
- Core Evidence Id
- 10763
- Source Meta Analysis Id
- 2156
- Herb2 Meta Analysis Id
- HBMA002156
- Crd Id
- CRD42017083392
- Title
- Fluphenazine decanoate (timing of administration) for people with schizophrenia [Cochrane protocol]
- Review Question
- To investigate the benefits and harm of administering fluphenazine decanoate at different time intervals for people with schizophrenia.
- Study Type Included
- We will include all relevant randomised controlled trials that investigate fluphenazine decanoate timing of administration for people with schizophrenia. We will include trials that are described as 'double-blind' in which randomisation is implied in a sensitivity analysis (see <link tag=SENSITIVITY_ANALYSIS type=SECTION/>Sensitivity analysis). If their inclusion does not result in a substantive difference, they will be retained in the analysis. If their inclusion does result in important clinically significant, but not necessarily statistically significant differences, we would not add the data from these lower-quality studies. We will exclude quasi-randomised studies, such as those that allocate intervention by alternate days of the week. Where people are given additional treatments as well as fluphenazine, we will only include data if the adjunct treatment is evenly distributed between groups and it is only the timing of fluphenazine administration that is randomised.
- Condition Being Studied
- The Cochrane Schizophrenia Group
- Participant
- Adolescents (aged 11 to 17 years) and adults (aged 18 years and over) with schizophrenia or related disorders, including schizophreniform disorder, schizoaffective disorder and delusional disorder, by any means of diagnosis. We are interested in making sure that information is as relevant as possible to the current care of people with schizophrenia, so aim to highlight the current clinical state clearly (acute, early post-acute, partial remission, remission), as well as the stage (prodromal, first episode, early illness, persistent), and whether the studies primarily focused on people with particular problems (for example, negative symptoms, treatment-resistant illnesses).
- Animal
- Human Disease Modelled
- Intervention
- <ol> Fluphenazine decanoate at any dose: administered every four weeks. Fluphenazine decanoate at any dose: administered in more than four-week intervals. Fluphenazine decanoate at any dose: administered in less than four-week intervals.</ol> For technical reasons the intervention and comparators fields for Cochrane protocols are identical and each may include information on both interventions and comparators
- Comparator Control
- <ol> Fluphenazine decanoate at any dose: administered every four weeks. Fluphenazine decanoate at any dose: administered in more than four-week intervals. Fluphenazine decanoate at any dose: administered in less than four-week intervals.</ol> For technical reasons the intervention and comparators fields for Cochrane protocols are identical and each may include information on both interventions and comparators
- Main Outcome
- <heading level=5>1. Global State</heading> 1.1 Clinically important changes in global state, as defined by each study 1.2 Clinically important change in compliance with treatment 1.3 Relapse <b>2. Mental state</b> 2.1 General 2.1.1 Clinically important change in overall mental state, as defined by each study<heading level=5>3. Quality of life</heading> 3.1 Clinically important changes in quality of life/satisfaction, as defined by each study<heading level=5>4. Adverse effects/events</heading> 4.1 Clinically important specific adverse effects - movement disorder, as defined by each of the studies
- Outcome Measure
- Additional Outcome
- <heading level=5>1. Global state</heading> 1.1 Any change in global state, as defined by each of the studies 1.2 Average endpoint/change score on global state scale <heading level=5>2. Mental state</heading><heading level=6>2.1 General</heading> 2.1.2 Any change in overall mental state, as defined by each study 2.1.3 Average endpoint/change scores on general mental state scale<heading level=6>2.2 Specific</heading> 2.2.1 Clinically important change in positive symptoms (e.g. delusions, hallucinations), as defined by each study 2.2.2 Any change in positive symptoms, as defined by each study 2.2.3 Average endpoint/change scores on positive symptom scale 2.2.4 Clinically important change in negative symptoms (e.g. affective flattening, alogia, or avolition), as defined by each study 2.2.5 Average endpoint/change scores on negative symptom scale<heading level=5>3. Quality of life</heading> 3.1 Any change in quality of life, as defined by each of the studies 3.2 Average endpoint/change score on quality of life scale<heading level=5>4. Adverse effects/event</heading> 4.1 At least one adverse effect/event 4.2 Clinically important specific adverse effects, as defined by each of the studies (e.g. anticholinergic, antihistamine, endocrinological, cardiovascular, genitourinary, gastrointestinal, neurological, respiratory, abnormal laboratory tests and any other specific adverse effects) 4.3 Average endpoint/change score on general adverse effect scale 4.4 Death - suicide or other causes<heading level=5>5. Service use</heading> 5.1 Hospital admissions 5.2 Duration of stay in hospital 5.3 Change in hospital status<heading level=5>6. Satisfaction with care for either recipients of care or caregivers</heading> 6.1 Clinically important change in satisfaction, as defined by each study 6.2 Any change in satisfaction, as defined by each study 6.3 Average endpoint/change scores on satisfaction scale<heading level=5>7. Leaving the study early</heading> 7.1 For any reason 7.2 Due to relapse 7.3 Due to adverse effects<heading level=5>8. Cognitive functioning</heading> 8.1 Clinically important change in cognitive functioning, as defined by each study 8.2 Any change in cognitive functioning, as defined by each study 8.3 Average endpoint/change score on cognitive functioning scale<heading level=5>9. Behaviour</heading> 9.1 Clinically important change in general behaviour, as defined by each study 9.2 Any change in general behaviour, as defined by each study 9.3 Average endpoint/change scores on general behaviour scale 9.4 Incidence aggression/violence.<heading level=5>10. Social functioning</heading> 10.1 Clinically important change in social functioning, as defined by each study 10.2 Any change in social functioning, as defined by each study 10.3 Average endpoint/change scores on social functioning scale<heading level=5>11. Economic costs</heading> 11.1 Costs due to treatment, as defined by each study 11.2 Savings due to treatment, as defined by each study<heading level=4>'Summary of findings' table</heading> We will use the GRADE approach to interpret findings (<link ref=REF-Schunemann-2011 type=REFERENCE/>Schunemann 2011); and will use GRADE profiler to create 'Summary of findings' tables. These tables provide outcome-specific information concerning the overall quality of evidence from each included study in the comparison, the magnitude of effect of the interventions examined, and the sum of available data on all outcomes we rate as important to patient care and decision making. We aim to select the following main outcomes for inclusion in the 'Summary of findings' table. Global state: Clinically important change in global state, as defined by each study - long-term Global state: Clinically important change in compliance with treatment Global state: Relapse Mental state: Clinically important change in overall mental state, as defined by each of the studies - long term Quality of life: Clinically important change in quality of life/satisfaction, as defined by each of the studies - long term Adverse effects/events: Clinically important specific adverse effects - movement disorder, as defined by each of the studies - medium term Satisfaction with care: Clinically important change in satisfaction, as defined by each of the studies</ul> If data are not available for these pre-specified outcomes but are available for ones that are similar, we will present the closest outcome to the pre-specified one in the table but take this into account when grading the finding.
- Study Method
- Intervention, Systematic review
- Keyword
- Antipsychotic Agents; Fluphenazine; Humans; Schizophrenia; fluphenazine depot
- Contact
- Fatima Abbas [email protected]
- Organisational Affiliation
- The Cochrane Collaboration http://www.cochrane.org/
- Funding Source
- Damascus University Syrian Private University Department of Obstetrics and Gynaecology, Damascus Manaaki Centre, Waikato District Health Board
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD012810/abstract
- Review Type
- Language
- English
- Country
- Syrian Arab Republic
- Review Stage
- Review Ongoing
- First Submission Date
- Registration Date
- 2017-12-04
- Anticipated Start Date
- 2017-10-15
- Anticipated Completion Date
- 2018-09-30
- Title Cn
- 氟奋乃静癸酸酯（给药时机）用于精神分裂症患者 [Cochrane方案]
- Title En
- Fluphenazine decanoate (timing of administration) for people with schizophrenia [Cochrane protocol]
- Bilingual Status
- complete